Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this FDA Warning Letter issued in September 2020 targets Pharmacy Plus, Inc., operating as Vital Care Compounder, a compounding pharmacy involved in drug manufacturing or preparation. While the specific violations are not detailed in the available metadata, the warning letter falls under FDA's drug product regulatory authority, suggesting potential compliance issues with pharmaceutical compounding practices or standards. Without access to the full letter text, the precise nature of the violations cannot be determined, but compounding pharmacies typically face citations related to sterility, quality control, or manufacturing practices.